Skip to main content

Table 2 Comparison of ICHOM outcome measures for macular degeneration and reported measures in study hospitals

From: Mapping standard ophthalmic outcome sets to metrics currently reported in eight eye hospitals

  Item Propose ICHOM Measure Reported measure in study hospitals Number of hospitals reporting Target Reported value
Visual functioning and vison-related quality of life Distance visual acuity Distance visual acuity (best of uncorrected, corrected, or pinhole) in the affected eye. Gain VA (15 ETDRS letters) after injections for macular degeneration 1/8 > 20% 20.7%
Visual stability (loss < 15 ETDRS letters) after injections for macular degeneration 1/8 > 80% 90.25%
Mobility and independence Impact of vision impairment questionnaire NA 0/8 None NA
Emotional well-being Impact of vision impairment questionnaire NA 0/8 None NA
Reading and accessing information Impact of vision impairment questionnaire NA 0/8 None NA
Disutility of care Number of treatments Documentation of individual treatments received for macular degeneration Appointment access and check in (% best response) 1/8 None ≈ 63%
Clinic wait times and comfort (% best response) 1/8 None ≈ 45%
Complications of treatment Endophthalmitis: severe intraocular inflammation within 3 months of last intraocular treatment Endophthalmitis after anti-VEGF intravitreal injections 5/8 None or 0.2–1.9%a 0.05% (MARINA) 0–0.18%
Disease control Presence of fluid, edema, or hemorrhage Presence of intraretinal or subretinal fluid or hemorrhage that is attributable to activity of the neovascular lesion NA 0/8 None NA
  1. ETDRS Early Treatment Diabetic Retinopathy Study, RD retinal detachment, VEGF vascular endothelial growth factor, PVR proliferative vitreo-retinopathy
  2. aBhavsar et al. Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required. Arch Ophthalmol 2009; 127(12): 1581–1583